We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

42 hedge funds and large institutions have $26.4M invested in Terns Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

5% less funds holding

Funds holding: 44 → 42 (-2)

8.39% less ownership

Funds ownership: 66.63% → 58.24% (-8.4%)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

47% less capital invested

Capital invested by funds: $50M → $26.4M (-$23.6M)

Holders
42
Holders Change
-2
Holders Change %
-4.55%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$2.52M
2
IC
Ikarian Capital
Texas
+$1.4M
3
AAA
Affinity Asset Advisors
New York
+$801K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$754K
5
AC
Armistice Capital
New York
+$645K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$6.97M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.43M
3
BlackRock
BlackRock
New York
-$1.17M
4
AC
Antara Capital
New York
-$400K
5
State Street
State Street
Massachusetts
-$286K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$6.63M – – –
RCM
2
RA Capital Management
Massachusetts
$3.13M +$2.52M +1,261,435 New
SCM
3
Suvretta Capital Management
New York
$3.07M – – –
AC
4
Antara Capital
New York
$2.17M -$400K -200,234 -19%
DCMIC
5
Decheng Capital Management III (Cayman)
Cayman Islands
$1.77M – – –
IC
6
Ikarian Capital
Texas
$1.74M +$1.4M +700,000 New
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$1.24M +$754K +377,427 +308%
AAA
8
Affinity Asset Advisors
New York
$995K +$801K +401,268 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$912K -$131K -65,490 -15%
SB
10
Samsara BioCapital
California
$717K – – –
Millennium Management
11
Millennium Management
New York
$689K +$378K +189,178 +214%
DCM
12
Driehaus Capital Management
Illinois
$521K +$349K +174,974 +499%
Renaissance Technologies
13
Renaissance Technologies
New York
$457K +$233K +116,616 +172%
BlackRock
14
BlackRock
New York
$371K -$1.17M -587,413 -80%
BFM
15
Boothbay Fund Management
New York
$265K +$213K +106,712 New
Fidelity Investments
16
Fidelity Investments
Massachusetts
$252K -$4.43M -2,219,783 -96%
CCM
17
CAAS Capital Management
New York
$242K +$23.3K +11,661 +14%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$196K -$200K -99,987 -56%
E
19
Ergoteles
New York
$157K +$127K +63,454 New
MAM
20
Marquette Asset Management
Minnesota
$144K +$72K +36,074 +165%
PI
21
PEAK6 Investments
Illinois
$123K +$28.2K +14,097 New
BCM
22
Bridgeway Capital Management
Texas
$113K -$34.4K -17,200 -27%
Citadel Advisors
23
Citadel Advisors
Florida
$96K +$77.5K +38,810 New
B
24
Bailard
California
$50K +$40.5K +20,300 New
State Street
25
State Street
Massachusetts
$49K -$286K -143,400 -88%
1
2 3

TERN Hedge Fund Activity: Q2 2022 in Review

42 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2022, worth a combined $26.4M — down 47% from $50M a quarter earlier.

Fund positioning in TERN was balanced in Q2 2022: 13 funds opened new positions, 13 closed out, 11 added to existing stakes and 13 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $2.52M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.97M sold.

  • 42 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2022, down from 44 in Q1 2022.
  • Funds reported $26.4M of Terns Pharmaceuticals stock for Q2 2022, down 47% quarter-over-quarter.
  • 13 funds opened new Terns Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of 0 holders.
  • The largest Terns Pharmaceuticals buyer in Q2 2022 was RA Capital Management, an estimated $2.52M added.
  • The largest Terns Pharmaceuticals seller in Q2 2022 was Deerfield Management, an estimated $6.97M sold.

Based on aggregated 13F filings for Q2 2022.